Source comparison
Comparison: CJC-1295 no DAC & Ipamorelin vs Alternatives
CJC-1295 no DAC & Ipamorelin GHRH analog + ghrelin agonist (dual pathway) 30 min (CJC) / 2 hr (Ipa) Low. Pulsatile dosing preserves receptor sensitivity Minimal (Ipamorelin is highly selective) Excellent. Pulsatile GH pattern mimics endogenous secretion, suppo
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC & Ipamorelin
- GHRH analog + ghrelin agonist (dual pathway)
- 30 min (CJC) / 2 hr (Ipa)
- Low. Pulsatile dosing preserves receptor sensitivity
- Minimal (Ipamorelin is highly selective)
- Excellent. Pulsatile GH pattern mimics endogenous secretion, supports multi-week protocols
- Exogenous recombinant GH
- Direct GH replacement
- 2–4 hours (depending on formulation)
- High. Continuous exposure causes receptor internalization within 14 days
- None (direct GH, bypasses secretagogue pathways)
- Moderate. Effective for acute studies but receptor fatigue limits extended protocols
- GHRP-6
- Ghrelin receptor agonist
- 30–45 minutes
- Moderate. Non-selective, affects multiple pathways
- Significant cortisol and prolactin increase
- Low. Hormonal confounders complicate lean tissue interpretation
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- 24 hours
- High. Continuous receptor stimulation
- Moderate cortisol elevation, appetite increase
- Moderate. Convenient dosing but tonic GH elevation reduces signal fidelity
- CJC-1295 with DAC
- GHRH analog with extended half-life
- 6–8 days
- Very high. Prolonged receptor occupancy causes downregulation
- Minimal
- Low. Extended half-life creates continuous GH elevation, unsuitable for pulsatile studies